Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
Source: SeekingAlpha
2026-01-30 12:53:14 ET
More on Protalix BioTherapeutics
- Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
- Protalix, Secarna in agreement to develop rare kidney disorder therapies
- Protalix BioTherapeutics GAAP EPS of $0.03 misses by $0.03, revenue of $17.67M misses by $0.2M
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
Read the full article on Seeking Alpha
For further details see:
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
Protalix BioTherapeutics Inc.
NASDAQ: PLX
PLX Trading
-2.67% G/L:
$2.915 Last:
597,039 Volume:
$3 Open:
PLX Latest News
January 30, 2026 09:47:43 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
December 17, 2025 06:50:00 am
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
November 13, 2025 06:50:00 am
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
PLX Stock Data
$215,126,659
70,448,955
0.23%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Hackensack
